1M6MYTD1Y5YMAX
Loading quotes...
Forecast
| Buy |
3 |
| Hold |
0 |
| Sell |
0 |
News Go to news feed
AIM ImmunoTech reports Q3 result: EPS improves to -1.57 USD
AIM ImmunoTech published figures for the quarter ended Sept. 30, 2025, with earnings per share (EPS) of -1.57 USD versus -6.00 USD in the prior year. Revenue was 0.0 million USD, down 25 percent from the year-ago quarter. The report contains no further operational details or outlook. » More on finanzen.net
Financials
| (EUR) | June 2026 | |
|---|---|---|
| Revenue | 22.78k | 7.41% |
| Gross profit | 18.4k | 44.59% |
| Net profit | -3.32m | 40.02% |
| EBITDA | -3.02m | 37.53% |
Fundamentals
| Metric | Value |
|---|---|
Market capitalization | €569.16k |
Number of shares | 3.4m |
52-week high/low | €2.46 - €0.16 |
| Dividends | No |
Beta | 1.19 |
P/E ratio | -0.05 |
PEG ratio | 0.00 |
P/B ratio | 0.42 |
P/S ratio | 6.81 |
Company profile
| Name | AIM ImmunoTech |
| CEO | Thomas K. Equels |
| Employees | 19 |
